Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

4.795 +0.445 (+10.23%)
Streaming Delayed Price Updated: 12:27 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Prime Medicine, Inc. - Common Stock

< Previous 1 2 Next >
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy
-- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- 
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Pricing of Public Offering
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Proposed Public Offering of Common Stock
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Unveils Strategically Focused Pipeline
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
From Prime Medicine, Inc.
Via GlobeNewswire
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
From Prime Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.